☰

Yvan H. Chanthery, Ph.D. - Publications

Affiliations: 
2011 Biomedical Sciences University of California, San Francisco, San Francisco, CA 
Area:
role of the cellular microenvironment and intercellular communication in breast development and cancer
Tree Info Similar researchers PubMed Report error

10 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2016 Vaughan L, Clarke PA, Barker K, Chanthery Y, Gustafson CW, Tucker E, Renshaw J, Raynaud F, Li X, Burke R, Jamin Y, Robinson SP, Pearson A, Maira M, Weiss WA, et al. Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumors. Oncotarget. PMID 27438153 DOI: 10.18632/Oncotarget.10544  0.775
2015 Cage TA, Chanthery Y, Chesler L, Grimmer M, Knight Z, Shokat K, Weiss WA, Gustafson WC. Downregulation of MYCN through PI3K Inhibition in Mouse Models of Pediatric Neural Cancer. Frontiers in Oncology. 5: 111. PMID 26029667 DOI: 10.3389/Fonc.2015.00111  0.769
2015 Li N, Maly DJ, Chanthery YH, Sirkis DW, Nakamura JL, Berger MS, James CD, Shokat KM, Weiss WA, Persson AI. Radiotherapy followed by aurora kinase inhibition targets tumor-propagating cells in human glioblastoma. Molecular Cancer Therapeutics. 14: 419-28. PMID 25522764 DOI: 10.1158/1535-7163.Mct-14-0526  0.721
2014 Gustafson WC, Meyerowitz JG, Nekritz EA, Charron EA, Chanthery Y, Simonds E, Matthay K, Hertz N, Shokat K, Weiss WA. Abstract 2688: Drugging MYCN through an allosteric transition in Aurora A kinase Cancer Research. 74: 2688-2688. DOI: 10.1158/1538-7445.Am2014-2688  0.651
2013 Puissant A, Frumm SM, Alexe G, Bassil CF, Qi J, Chanthery YH, Nekritz EA, Zeid R, Gustafson WC, Greninger P, Garnett MJ, Mcdermott U, Benes CH, Kung AL, Weiss WA, et al. Targeting MYCN in neuroblastoma by BET bromodomain inhibition Cancer Discovery. 3: 309-323. PMID 23430699 DOI: 10.1158/2159-8290.Cd-12-0418  0.742
2012 Chanthery YH, Gustafson WC, Itsara M, Persson A, Hackett CS, Grimmer M, Charron E, Yakovenko S, Kim G, Matthay KK, Weiss WA. Paracrine signaling through MYCN enhances tumor-vascular interactions in neuroblastoma. Science Translational Medicine. 4: 115ra3. PMID 22218692 DOI: 10.1126/scitranslmed.3002977  0.703
2011 Chanthery YH, Gustafson WC, Weiss WA. Abstract 1558: Paracrine signaling through Mycn enhances tumor-vascular microenvironment in neuroblastoma Cancer Research. 71: 1558-1558. DOI: 10.1158/1538-7445.Am2011-1558  0.774
2010 Swarbrick A, Woods SL, Shaw A, Balakrishnan A, Phua Y, Nguyen A, Chanthery Y, Lim L, Ashton LJ, Judson RL, Huskey N, Blelloch R, Haber M, Norris MD, Lengyel P, et al. miR-380-5p represses p53 to control cellular survival and is associated with poor outcome in MYCN-amplified neuroblastoma. Nature Medicine. 16: 1134-40. PMID 20871609 DOI: 10.1038/Nm.2227  0.7
2006 Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Singh M, Chien M, Tan C, Hongo JA, de Sauvage F, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature. 444: 1083-7. PMID 17183323 DOI: 10.1038/Nature05313  0.355
2006 Yao VJ, Ozawa MG, Varner AS, Kasman IM, Chanthery YH, Pasqualini R, Arap W, McDonald DM. Antiangiogenic therapy decreases integrin expression in normalized tumor blood vessels. Cancer Research. 66: 2639-49. PMID 16510583 DOI: 10.1158/0008-5472.Can-05-1824  0.427
Show low-probability matches.